Clinical trial NCT02616601: Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
Official title: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Fluorouracil Cream, 0.5% and Carac® (Fluorouracil) Cream, 0.5% in Subjects With Actinic Keratoses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Actinic Keratosis
Lead sponsor: Actavis Inc.
Sponsor class: INDUSTRY
First posted: 2015-11-30
Enrollment: 422
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.

Detailed description: This is a multicenter, double-blind, vehicle-controlled, parallel group comparison study of a generic fluorouracil cream, 0.5% and Carac (fluorouracil) Cream, 0.5% in participants with actinic keratoses on the full face or balding scalp.

Eligibility criteria: Inclusion Criteria:

* Participant is male and/or female, 18 years of age or older.
* Participant is willing and able to give written informed consent.
* Participant is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
* Participant has a clinical diagnosis of actinic keratoses with at least 5 and no more than 10 clinically typical, visible or palpable, discrete, actinic keratoses (AK) lesions, each at least 4 millimeters (mm) in diameter on the face (excluding ears) or balding scalp.
* Participant is in good general health and free of any disease state or physical condition that might impair evaluation of AK lesions or which, in the investigator's opinion, exposes the participant to an unacceptable risk by study participation.
* Females must be post-menopausal, surgically sterile, or use an effective method of birth control with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion Criteria:

* Participant is pregnant, lactating, or is planning to become pregnant during the study.
* Participant is currently enrolled in an investigational drug or device study.
* Participant has used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
* Participant has hyperkeratotic, hypertrophic, or large mat-like AK lesions (for example, an AK lesion \>1 cm\^2 in size) within the treatment area.
* Participant has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
* Participant is immunosuppressed (for example, human immunodeficiency virus (HIV), systemic malignancy, graft host disease)
* Participant has experienced an unsuccessful outcome from previous topical fluorouracil therapy (an unsuccessful outcome is defined as after a reasonable therapeutic study with no compliance issues and the topical drug did not work).
* Participant has a history of sensitivity to any of the ingredients in the test articles.
* Participant has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.
* Participant used topical creams, lotions, or gels of any kind within the selected treatment area within 1 day prior to entry into the study.
* Participant has used topical medications; corticosteroids, alpha hydroxy acids (for example, glycolic acid, lactic acid, etc. \>5%), beta hydroxy acid (salicylic acid \>2%), urea \>5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate; or prescription retinoids (for example, tazarotene, adapalene, tretinoin) within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
* Participant has had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
* Participant has used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within 1 month prior to the Baseline Visit.
* Participant has had dermatologic procedures or surgeries such as: laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B therapy, chemical peels, or dermabrasion within the selected treatment area (face or balding scalp) within 6 months prior to the Baseline Visit.
* Participant has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected treatment area (face or balding scalp).
* Participant has any skin pathology or condition on the face or balding scalp that, in the Investigator's opinion, could interfere with the evaluation of the test article or requires the use of interfering topical, systemic, or surgical therapy.
* Participant has any condition which, in the Investigator's opinion, would make it unsafe or preclude the participant's ability to fully participate in this research study.
* Participant is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.
* Participant is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (for example, due to alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator.
* Participant has been previously enrolled in the same study.

Primary outcomes:
measure: Percentage of Participants With Treatment Success (Complete Clearance) at Week 6
timeFrame: Week 6
Secondary outcomes:
Other outcomes:
Locations:
city: Fremont
country: United States
facility: Investigative Site 2
state: California
city: Los Angeles
country: United States
facility: Investigative Site 16
state: California
city: San Diego
country: United States
facility: Investigative Site 17
state: California
city: Denver
country: United States
facility: Investigative Site 4
state: Colorado
city: Newnan
country: United States
facility: Investigative Site 10
state: Georgia
city: Boise
country: United States
facility: Investigative Site 5
state: Idaho
city: Arlington Heights
country: United States
facility: Investigative Site 1
state: Illinois
city: Buffalo Grove
country: United States
facility: Investigative Site 11
state: Illinois
city: Carmel
country: United States
facility: Investigative Site 3
state: Indiana
city: Plainfield
country: United States
facility: Investigative Site 9
state: Indiana
city: South Bend
country: United States
facility: Investigative Site 6
state: Indiana
city: Clinton Township
country: United States
facility: Investigative Site 8
state: Michigan
city: Warren
country: United States
facility: Investigative Site 13
state: Michigan
city: Fridley
country: United States
facility: Investigative Site 12
state: Minnesota
city: Albuquerque
country: United States
facility: Investigative Site 15
state: New Mexico
city: High Point
country: United States
facility: Investigative Site 7
state: North Carolina
city: Philadelphia
country: United States
facility: Investigative Site 14
state: Pennsylvania
Study officials:
affiliation: Actavis Inc.
name: Study Director
role: STUDY_DIRECTOR
References: